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Abstract
Prostate cancer is influenced by epigenetic modification of genes involved in cancer development and progression.
Increased expression of Prostate Stem Cell Antigen (PSCA) is correlated with development of malignant human prostate
cancer, while studies in mouse models suggest that decreased PSCA levels promote prostate cancer metastasis. These
studies suggest that PSCA has context-dependent functions, and could be differentially regulated during tumor
progression. In the present study, we identified the multi-functional transcription factor Yin Yang 1 (YY1) as a modulator of
PSCA expression in prostate epithelial cell lines. Increased YY1 levels are observed in prostatic intraepithelial neoplasia (PIN)
and advanced disease. We show that androgen-mediated up-regulation of PSCA in prostate epithelial cell lines is dependent
on YY1. We identified two direct YY1 binding sites within the PSCA promoter, and showed that the upstream site inhibited,
while the downstream site, proximal to the androgen-responsive element, stimulated PSCA promoter activity. Thus,
changes in PSCA expression levels in prostate cancer may at least partly be affected by cellular levels of YY1. Our results also
suggest multiple roles for YY1 in prostate cancer which may contribute to disease progression by modulation of genes such
as PSCA.
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Introduction
Prostate cancer is a heterogeneous disease arising from genetic
events such as Pten deletion which result in tumor initiation [1,2,3].
Epigenetic gene regulation may augment tumor initiation in
conjunction with the oncogenic signal and is known to modulate
tumor progression [4]. Thus it is critical to understand
transcriptional and translational control mechanisms which
influence tumor progression, as these pathways may provide novel
therapeutic opportunities for advanced disease.
Prostate Stem Cell Antigen (PSCA) is a GPI-anchored cell
surface protein [5] and is a marker of the transiently amplifying
cell population within prostate epithelium [6]. PSCA is also
expressed in epithelial cells of various organs including the kidney,
bladder, stomach and pancreas [7]. PSCA over-expression is
reported in a subset of prostate cancers at all stages from PIN to
metastatic disease [8]. Although this protein has been considered
as a target for therapy [8,9] and imaging [10] of prostate cancer,
its function is still unknown. Studies of human prostate cancers
suggest that expression of PSCA in PIN is a predictor of later
development of invasive adenocarcinoma [11]. In addition our
studies in a murine prostate cancer model showed that loss of
PSCA promotes tumor metastasis [12]. Together, these data
suggest that changes in PSCA expression levels may alter tumor
development and progression.
PSCA is an androgen-responsive gene and expression in the
prostate is modulated in response to systemic changes in androgen,
through interaction of androgen receptor (AR) with an androgen-
responsive element (ARE) [13]. However, other control mecha-
nisms must be involved, since PSCA is expressed in castration-
resistant prostate cancer [5], and in androgen-insensitive organs
such as the kidney, stomach, pancreas and bladder [7].
The transcription factor Yin Yang 1 (YY1) [14] is expressed in
normal tissues and is up-regulated in various cancers including
prostate cancer, with positive and negative regulatory effects on
gene expression [15,16]. Elevated YY1 expression is correlated
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[15,17,18]. Although the function of YY1 in prostate cancer is
not fully known, it was reported recently that YY1 forms a
complex with AR, which together binds to the ARE within the
PSA promoter, stimulating gene expression [19]. Thus, YY1 has a
role in epigenetic regulation of prostate cancer genes.
In this study, we demonstrated that androgen-mediated
stimulation of PSCA expression requires YY1. In addition, we
identified two direct YY1 binding sites within the upstream region
of the PSCA gene. Deletion analysis showed that the upstream site
represses PSCA promoter activity, while the downstream site
stimulates promoter activity. Furthermore, knockdown of YY1 in
prostate cancer cell lines increased endogenous PSCA message,
suggesting that changes in PSCA message levels during prostate
cancer progression may be at least partially regulated by YY1.
Materials and Methods
Cell lines
Pten P8 and Pten CaP8 cells were provided by Dr. Hong Wu
(UCLA) and maintained as described [20]. LNCaP cells [21]
provided by Dr. Owen Witte (UCLA) and PC-3 cells (ATCC,
[22]) were maintained in RPMI with 10% fetal bovine serum.
HEK293T cells [23] were a gift of Dr. Owen Witte.
PSCA promoter constructs
The murine PSCA genomic clone was a gift of Dr. Owen Witte.
The 24.5 kb EcoRI promoter fragment was isolated by restriction
digest from pBluescript and cloned into the EcoR1 site of pGLuc-
Basic (Promega). To generate site-specific mutations of the YY1
binding sites, a 2 kb BamHI fragment of the promoter isolated
from pGLuc-4.5.kb was sub-cloned into pBluescript. Mutations
were performed essentially as described in the Stratagene Quik-
change PCR kit using the following primers: mPSCA Site 1
primer: 59-GGCTTTAACTTCCAGAACCCAACGCGTGGA-
CCATAGTGGGAGAGG-39 and mPSCA Site 2 primer 59-CC-
CTGGGACAGCTGGGTCGACCTCTGCCCGTGATTC-39.
The mutated nucleotides are underlined.
A MluII restriction site was introduced in mPSCA Site 1 and a
Sal I site was introduced in mPSCA Site 2 (restriction sites bold
and italicized) to facilitate identification of colonies containing the
mutations, and was confirmed by sequencing of the fragment. The
BamHI fragments containing one or both of the mutations were
replaced into the pGLuc-4.5 kb promoter construct.
Production and purification of recombinant YY1 protein
The HA-YY1 cDNA was PCR amplified from pcDNA3.1-HA-
YY1using Pfu Ultra DNA polymerase (Stratagene, Agilent Tech-
nologies) with sense primer 59-AGTCCGGAATTCGCCACCAT-
GTGCTACCCATACGATGTTC-39 and antisense primer 59-
AGTCCGGAATTCTCACGGCTGGTTGTTTTTGGCCTTA-
GCA-39 (EcoRI sites are underlined; Kozak’s consensus sequence is
bolded; ATG and stop codon are italicized), digested with EcoRI
and ligated into the unique EcoRI site of the pVL1392 baculovirus
transfer vector (BD Biosciences). HA-YY1 baculovirus stock was
prepared following manufacturer’s instructions by co-transfecting
Spodoptera frugiperda Sf9 cells with 4 mg of pVL1392-HA-YY1 and
0.5 mg of baculovirus gold DNA (BD Biosciences) per 2610
6 cells/
60 mm. Sf9 cells were maintained in Grace’s medium containing
10% FBS, Yeastolate, lactalbumin hydrolysate, and gentamicin
(Invitrogen). Low titer stock was harvested and 40 mL was infected
into 1610
7 Sf9 cells for amplification, and high titer HA-YY1
baculovirus stock was harvested and stored at 4uC until use. For
HA-YY1 protein expression, 500 mL of the HA-YY1 baculovirus
stock was used to infect 1610
7 Sf9 cells/10 mL. Forty-eight hours
later, the infected cells were harvested in EBC buffer plus protease
inhibitors [24]. HA-YY1 was isolated from the Sf9 lysate using
EZview Red Anti-HA Affinity Gel (Sigma) according to manufac-
turer’s instructions and analyzed by SDS-PAGE. Protein concen-
tration was determined using protein standards (BioRad). HA-YY1
wasverifiedbyWesternblottingwithmonoclonalYY1antibody(H-
10, Santa Cruz Biotechnology).
Electrophoretic Mobility Shift Assay (EMSA)
EMSA was performed as described previously [25,26]. A 500-
bp fragment encompassing each binding site was generated by
PCR and cloned into pBluescript using the KpnI and EcoRI
enzymes in the primer sequences. The plasmids were first digested
with Kpn I, end-labeled with c-
32P-dATP using T4 polynucleotide
kinase (New England Biolabs), and then digested with EcoRI.
Excess unincorporated radioactivity was removed by purification
through a G-50 quick-spin column (GE Healthcare). Reactions
containing the radiolabeled fragment, purified HA-YY1 protein
and 16binding buffer [10 mM Tris-HCl (pH 7.8), 2 mM MgCl2,
50 mM NaCl, 1 mM dithiothreitol, 100 ng of bovine serum
albumin, 10% glycerol] in 20 ml volume, were incubated at 37uC
for 15 min to allow DNA-protein binding. The samples were
electrophoresed on a 5% polyacrylamide gel and visualized by
autoradiography.
Chromatin immunoprecipitation
Chromatin immunoprecipitation (ChIP) assays were carried out
as described previously [27]. Precipitated DNA was analyzed by
PCR using primers specific for the human and murine upstream
and downstream YY1 binding sites. Human PSCA downstream
site (hPSCA1) primers: FWD-59-GTGGTGGCCTTTCGTTAG-
C-39 and REV-59-GGCCCTGTCAAATGCCACTC; human
upstream site (hPSCA2) primers: FWD-59-GGACGGGATCAC-
TTGGTCTC-39 and REV-59-GGGCTGAGAGGCTGATGT-
GA-39. Murine PSCA downstream site (mPSCA1) primers: FWD-
59CGGGGTACCGCACTGTGAGCCAAAACC-39 and REV-
59-CCCAAGCTTGGCGTCATGTGCCAAGC-39; murine up-
stream site (mPSCA2) primers: FWD-59-GCCTGTGGAGCTT-
CAGCCCA-39 and REV-59-CAGACCTCTACCTCTTCT-39.
Beta actin primers used as negative control were: FWD-59-
CACAGGCATTGTGATGGACT-39 and REV-59-CTCACAG-
GATGCAGAAG-39.
PCR products were analyzed on a 1% agarose gel and
visualized by ethidium bromide.
Lentiviral infection
LNCaP or PC3 cells were plated in 6-well plates (Corning) at a
density of 1610
5 cells/well, 12–18 hours prior to infection in their
respective culture medium. The next day, concentrated lentivirus
was added to the well at a 1:100 dilution with 8 mg/ml polybrene
(Sigma). The virus was removed after 8–15 hours of incubation
and fresh medium was added to the wells. Cells were trypsinized
and harvested for analysis 48–60 hours following infection.
R1881 stimulation
For stimulation with synthetic androgen, cells were cultured for
24 hr in Pten medium prepared using phenol-red free DMEM
with 10% charcoal-stripped serum. Androgen analog R1881
Modulation of PSCA Expression by YY1
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additional 24 hr of culture [19].
Transient transfection
HEK293T cells were transiently transfected in triplicate with
3 mg of DNA (2.5 mg pGLuc2 plasmids containing the intact
promoter or the site-specific mutations, with 0.5 mg dsRed-
containing plasmid for transfection control) using GeneJuice
(Novagen) and the manufacturer’s protocol. Expression of dsRed
and luciferase activity was determined 72 hr post-transfection.
Quantitative real-time PCR analysis
RNA was extracted from prostate cancer cell lines using the
Qiagen RNEasy isolation kit and manufacturer’s instructions.
Human and murine PSCA message levels were determined using
TaqMan Gene Expression assay kits (Applied Biosystems) and
following manufacturer’s instructions. Analysis was performed on
an ABI 7700 real-time PCR machine, using the relative
quantitation method. Normalization was performed using human
GAPDH and murine beta actin, also using TaqMan Gene
Expression assay kits.
Luciferase assays
Infected cells were lysed in Passive Lysis Buffer (Promega) and
Gaussia luciferase activity was assessed using 2 mg/ml coelenter-
azine in DMEM as a substrate, and read in a luminometer.
Luciferase activity was normalized to the percentage of dsRed-
expressing cells in each well.
Flow cytometry
Cell surface PSCA protein levels were quantified by staining cell
lines with rabbit polyclonal anti-PSCA antibody (0.2 mg/ml, Santa
Cruz Biotechnology) followed by goat anti-rabbit-APC (1:1000)
and analyzed on a BD Facscalibur instrument using Cellquest
ProH software. Expression of dsRed in live cells was analyzed on
the FACSCalibur.
Results
Recombinant YY1 directly binds to predicted binding
elements in the human and murine PSCA promoters
PSCA responses to systemic androgen are mediated through an
androgen-responsive element (ARE) in the human and murine
promoter regions. However, regulatory mechanisms which
modulate PSCA expression in the prostate in the absence of
androgen, or in other epithelial tissues, are undefined. In order to
identify other putative control mechanisms, we scanned the
human and murine PSCA sequences using the TFSearch
algorithm [28] to determine whether other transcription factors
with a role in epithelial cancer development and progression may
also interact with the PSCA promoter. A previous study showed
that expression in a transgenic mouse of a Green Fluorescent
Protein (GFP) reporter gene behind 29 kb PSCA upstream region
replicated the expression pattern of endogenous PSCA [29].
Subsequent work showed that the shorter 26 kb upstream region
[13] maintained promoter activity and specificity and contained
the ARE. Therefore, we limited our analysis to the 26 kb regions
of the human and murine PSCA promoters.
Figure 1. Schematic diagram of predicted YY1 binding sites in the human and murine PSCA promoter. A. Two YY1 binding sites (shown
as diamonds) predicted by the TFSearch algorithm are located upstream of an ARE (triangles) in both the human and murine promoter; B. Nucleotide
sequence alignment of these sites to consensus YY1 binding sites [30] shows significant homology.
doi:10.1371/journal.pone.0035570.g001
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these sequences. Figure 1A shows the relative location of the
binding sites compared to the previously identified ARE within
these promoters [13], and in relation to the transcription initiation
site previously identified for the hPSCA promoter. The nucleotide
sequence of the sites and homology to the consensus YY1 site [30]
is shown in Figure 1B. The downstream site, mPSCA1 is adjacent
to the ARE. No putative ARE was identified adjacent to the
upstream site, mPSCA2.
To determine whether both of the putative YY1 binding sites in
the murine PSCA promoter bound purified YY1 in vitro,w e
conducted EMSA analysis. We used recombinant human HA-
tagged YY1 for our studies, since human and murine YY1 proteins
share 97% similarity, with 100% identity in their zinc finger DNA-
binding domains. Recombinant HA-YY1 was produced in SF9
insect cells, purified using the HA tag (Figure 2A) and verified by
Western blot (Figure 2B). Binding of the recombinant protein to
the downstream predicted site (mPSCA1) (Figure 2C) and the
upstream site (mPSCA2) (Figure 2D) was observed and was
competed by non-radioactive specific DNA but not by poly dI-dC
as non-specific competitor. At higher concentrations of SF9-YY1
protein, there was no change in the mobility of the DNA-protein
complex for mPSCA2. Therefore fewer lanes are shown in
Figure 2C than in Figure 2D.
Chromatin immunoprecipitation assay using anti-YY1
antibody detects human and murine PSCA upstream
sequences from prostate cancer cell lines
To determine interaction of YY1 with the PSCA promoter in
vivo, we conducted chromatin immuno-precipitation analysis
(ChIP) using human and murine prostate cancer cell lines. LNCaP
cells are a human androgen-dependent prostate cancer cell line
Figure 2. Recombinant YY1 protein binds specifically to murine PSCA promoter fragments. A. Coomassie stained polyacrylamide gel
shows purity of HA-tagged YY1 protein produced in Sf9 insect cells. B. Western blot using anti-HA antibody confirms size and integrity of
recombinant YY1. C. EMSA analysis using a 500 bp fragment including the downstream YY1 binding site (mPSCA1) in the murine promoter shows
specific binding of YY1 to this fragment. Specific competitor is unlabeled promoter fragment and non-specific competitor is poly dIdC. D. EMSA
analysis using a 500 bp fragment including the upstream YY1 binding site (mPSCA2) in the murine promoter shows specific binding of YY1 to this
fragment. Specific competitor is unlabeled promoter fragment and non-specific competitor is poly dIdC.
doi:10.1371/journal.pone.0035570.g002
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which developed in a prostate-specific Pten knockout mouse [20].
Immunoprecipitation was conducted using a murine anti-YY1
monoclonal antibody and genomic DNA was analyzed by PCR.
The upstream and downstream YY1 binding sites were specifically
immunoprecipitated in both LNCaP and Pten CaP8 cell lines,
demonstrating interaction of endogenous YY1 with the PSCA
promoter (Figure 3). Thus, interaction of YY1 with the PSCA
promoter occurs in vivo, and has the potential to modulate PSCA
expression in human and murine prostate cancer cell lines.
Mutation of the direct YY1 binding sites modulates
mPSCA promoter activity
YY1 binding to promoters can either inhibit or stimulate
transcription [31,32]. To determine whether YY1 binding
positively or negatively regulated PSCA promoter activity, we
generated reporter constructs where 4.5 kb of the mPSCA
promoter controlled expression of the Gaussia luciferase reporter.
Site-specific mutations of mPSCA1 and mPSCA2 were introduced
alone or together into the 24.5 kb promoter. HEK293T cells
were transiently transfected with the reporter constructs along with
a dsRed-expressing vector to determine transfection efficiency.
Transfected cells were analyzed 72 hr later. Mutation of three
nucleotides in mPSCA2 increased luciferase activity several
hundred-fold compared to the intact construct (Figure 4). In
contrast, mutation of mPSCA1 by changing 3 nucleotides
repressed promoter function (Figure 4). Mutation of both binding
sites generated intermediate luciferase activity, showing opposing
functions for the two binding sites. Thus, YY1 may exert dual
control on PSCA promoter expression.
YY1 is required for R1881-mediated stimulation of PSCA
expression
The binding of AR to ARE sequences within promoters can
either stimulate or inhibit gene transcription and is dependent on
the cofactors recruited to the site. It was recently reported by one
of us [19] that AR stimulation of PSA transcription requires YY1,
and is mediated by an AR-YY1 protein complex which binds to
the ARE. mPSCA1 is separated from the previously defined AREs
within the PSCA promoter by approximately 200 nucleotides. To
determine whether AR-mediated stimulation of PSCA expression
also required YY1, we investigated the effect of YY1 knockdown
on endogenous PSCA protein and message levels.
Pten CaP8 and Pten CaP2 cells are cell lines derived from the
tumors of prostate-specific Pten knockout mice [20]. Pten CaP8
and Pten CaP2 cells were cultured in androgen-depleted
conditions for 48 hours. The androgen analog R1881 or vehicle
was added to the cells and cell surface PSCA expression was
determined 48 hours later by flow cytometry. PSCA expression
was increased following R1881 stimulation of Pten CaP8 and Pten
CaP2 cells (Figure 5A, upper panels). To determine whether
knockdown of endogenous YY1 influenced stimulation of PSCA
protein levels by R1881, the cells were infected with a lentivirus
expressing YY1siRNA [33] and GFP or with GFP-expressing virus
alone followed by androgen deprivation and stimulation of the
infected cells. Infection with the YY1 knockdown construct
resulted in a 50% reduction in cell-surface PSCA levels following
R1881 stimulation compared with vector infected Pten CaP8 cells
(Figure 5A, lower panel), while YY1 knockdown abrogated the
increase in cell-surface PSCA levels in Pten CaP2 cells.
Knockdown of YY1 was achieved with greater than 90%
efficiency in both cells (Figure 5B). Thus, YY1 expression is
necessary for androgen-mediated stimulation of PSCA expression.
Both Pten CaP2 and Pten CaP8 cells die 96 hours following
YY1siRNA infection (data not shown) suggesting that YY1
knockdown adversely affects viability of these cells.
To determine whether the change in PSCA protein was a result
of transcriptional modulation, Pten CaP2 cells infected with the
YY1siRNA construct, or dsRed vector alone, were evaluated for
changes in endogenous PSCA message levels. Real-time quanti-
tative PCR analysis showed that PSCA message levels were
reduced by knockdown of YY1 (Figure 5C), and a slight, but not
statistically significant increase (p=0.09) was observed following
R1881 stimulation of the YY1siRNA infected cells. This increase
in PSCA message could be the result of better cell viability in
hormone-replete medium, or stimulation of expression from the
residual YY1 present in the cells.
Figure 3. Chromatin immunoprecipitation analysis detects
binding of YY1 to the human and murine PSCA promoter. A.
PCR primers flanking the predicted upstream and downstream YY1
binding sites for murine and human predicted YY1 binding sites and
the control b-actin are shown. B. The cross-linked YY1-DNA complex
was immunoprecipitated with a murine anti-YY1 monoclonal antibody
or an isotype control antibody. The YY1 binding DNA fragment was
amplified from both samples using the primers shown in A and
visualized by agarose gel electrophoresis. Input samples were loaded as
a control.
doi:10.1371/journal.pone.0035570.g003
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prostate cancer cells
To determine whether YY1 also modulates human PSCA
expression, we determined the effect of YY1 knockdown in an
androgen-dependent human prostate cancer cell line, LNCaP, and
an androgen-independent human prostate cancer cell line, PC-3.
LNCaP cells were infected with YY1siRNA lenvirus or dsRed
control virus, and RNA was purified 72 hr later. There was no
significant change in human PSCA message levels in LNCaP cells
(Figure 6A), despite nearly 100% infection of the cells (not shown)
and efficient knock down of YY1 protein (Figure 6B). These results
suggest that in a cell line with functioning androgen receptor, the
positive and negative effects of YY1 are cancelled out by
knockdown of YY1, resulting in no net change in PSCA expression
levels.
To determine whether YY1 regulates PSCA expression without
the contribution of AR, the effect of YY1 knockdown was
evaluated in PC-3 cells, which contain mutant AR. PC-3 cells were
infected with the YY1siRNA lentivirus or dsRed control virus, and
RNA was purified 72 hr later. Quantitative RT-PCR analysis
showed that infection with YY1siRNA significantly increased
endogenous PSCA expression in PC-3 cells (Figure 6C). Nearly
100% of the cells were infected (data not shown) resulting in
effective knockdown of YY1 protein expression (Figure 6D). These
data suggest that YY1 represses PSCA expression in androgen-
independent prostate cancer cells.
Discussion
Levels of PSCA protein and message vary in prostate cancer
and may be affected by different modifiers during tumor
progression. Previous work showed that PSCA expression is
reduced after castration [29,34], and increased when androgen is
provided exogenously, likely due to binding of androgen to an
ARE within the PSCA promoter [13]. In this study, we
demonstrated that the multifunctional transcriptional factor YY1
binds directly to the PSCA promoter and regulates PSCA
expression in androgen-dependent and independent cell lines.
The increase in cell surface PSCA protein levels following
stimulation with a synthetic androgen analog was regulated by
YY1. We observed a partial reduction in cell surface PSCA levels
in Pten CaP8 cells following YY1 knockdown and R1881
stimulation. The low levels of YY1 still present in the cells may
be sufficient for interaction with AR and stimulation of PSCA
Figure 4. Mutation of YY1 binding sites mPSCA1 and mPSCA2 has opposing effects on PSCA promoter activity. A. Schematic
representation of constructs with mutations of the YY1 binding sites in the mPSCA promoter (¤, YY1 binding site, m, ARE, X, site of mutation). B. The
primer sequences used to generate the mutations are shown. A restriction site (bold and italicized) was introduced to identify the mutation and is
shown in the lower line (labeled MUT) for each binding site. The mutated nucleotides are underlined. C. HEK293T cells were transiently transfected
with the intact or mutant promoter constructs along with dsRed expressing vector as transfection control. Cells were harvested 72 hr later and
analyzed by flow cytometry for dsRed expression. Gaussia luciferase activity in cell supernatant was measured and normalized to the percentage of
dsRed positive cells (data not shown). Each infection was done in triplicate. One representative experiment is shown and the experiment was
repeated twice. *, p,0.005 compared with intact construct; p,0.03 compared with upstream and downstream mutations.
doi:10.1371/journal.pone.0035570.g004
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alone or in conjunction with other cofactors. Complete inhibition
of PSCA expression in Pten CaP2 cells after YY1 knockdown
suggests strong dependence on YY1 for R1881-mediated stimu-
lation of PSCA expression. An earlier report showed that an AR-
YY1 complex bound to the ARE in the human PSA promoter,
and stimulated transcription [19]. Our in vitro data showed that
promoter activity was abrogated when the mPSCA1 site adjacent
to the ARE was mutated, suggesting that YY1 binding to this site
mediates upregulation of PSCA together with AR. Our results do
not exclude the possibility that an AR-YY1 complex is also
binding to the ARE, and optimal stimulation of PSCA expression
by AR may require both of these interactions.
Figure 5. Knockdown of YY1 reduces androgen-mediated up-regulation of PSCA on the cell surface. A. Pten CaP8 and Pten CaP2 cells
were incubated in hormone-depleted medium for 48 hours and then treated with 10 nM R1881 or vehicle (upper panels). Pten CaP2 and Pten CaP8
cells were infected with a lentivirus expressing YY1 specific siRNA or dsRed expression virus as control. Cells were then androgen deprived and
treated with 10 nM R1881 for 48 hours (lower panels). Cell surface PSCA expression was determined by FACS using a polyclonal rabbit anti PSCA
antibody. B. Expression of YY1 in Pten CaP8 and Pten CaP2 cells infected with YY1 siRNA expressing or control lentivirus was determined by Western
blot. The blot was re-probed with anti-b-actin as a loading control. C. Quantitative real-time PCR analysis for PSCA expression was conducted on RNA
extracted from Pten CaP2 cells in A.
doi:10.1371/journal.pone.0035570.g005
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expression levels of PSCA in the different stages of prostate cancer.
YY1 expression is elevated in PIN and intermediate stage disease
[15,18], and its interaction with AR may result in increased PSCA
expression in PIN and well-differentiated cancers. Similarly,
changes in YY1 levels together with changes in systemic androgen
may modulate PSCA expression during tumor progression.
Increased reporter gene activity from the promoter construct
with mutation of the distal YY1 binding site, mPSCA2, suggested
that this is an inhibitory site. In an androgen-independent cell line,
PC-3, knockdown of YY1 increased PSCA message. Although we
cannot exclude the possibility that other mutations acquired by
PC-3 cells may contribute to the downregulation of PSCA by
YY1, our data strongly suggest that YY1 may inhibit PSCA
expression in advanced prostate cancer. In murine and human
androgen-dependent cell lines, YY1 knockdown did not increase
endogenous PSCA message. However, by knocking down YY1
levels, we also prevented stimulation of PSCA transcription by AR.
Thus, the potential increase in transcription by preventing YY1
binding to the inhibitory sites may be offset by the reduction in
AR-mediated transcription.
The direct binding of YY1 to gene regulatory sequences can be
either stimulatory or inhibitory, and depends on the associated
recruited cofactors [31,32]. Here we show that YY1 can both
inhibit and stimulate the same promoter through interaction with
different YY1 binding sites in the promoter, an observation also
made previously for other promoters [35,36]. Thus, regulation of
PSCA by YY1 is likely to be context-dependent and modulated
during tumor progression.
Although PSCA upregulation by androgen was defined some
time ago, the mechanism by which PSCA expression is decreased
in a subset of prostate cancers and in other epithelial cancers is
unknown. Our data suggest repression of PSCA promoter activity
by YY1 as one potential mechanism for reduced PSCA expression.
The earlier description of regulation of the PSA promoter by an
YY1-AR complex [19], together with the present work, suggests
that YY1 may influence prostate cancer progression by regulation
of at least two prostate cancer genes.
The role of YY1 in non-androgen dependent epithelial cancers
such as bladder and pancreas, where PSCA is also expressed, is
presently unknown. Elevated YY1 levels in these cancers may
decrease PSCA levels by direct binding of YY1 to the inhibitory
site in the promoter. Clinical data show that PSCA is up-regulated
in bladder carcinoma in situ and down-regulated in invasive and
advanced disease [37]. Recently, a single nucleotide polymor-
phism which reduced PSCA expression in human bladder [38]
and gastric cancer [39] was associated with more aggressive
disease. Down-regulation of PSCA expression by YY1 may
similarly reduce PSCA expression and promote disease progres-
sion in these cancers. Further exploration of PSCA regulation by
YY1 in other epithelial cancers will help to elucidate this
mechanism.
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Figure 6. YY1 knockdown in an androgen-independent
prostate cancer cell line upregulates endogenous PSCA
message levels. A. LNCaP cells (2610
5/well) were infected in triplicate
with YY1siRNA or scrambled control, and evaluated 72 hr later. PSCA
message was determined by quantitative real-time PCR analysis. B. The
amount of endogenous YY1 protein in YY1siRNA- or scramble control-
infected cells was determined by Western blot. Representative analysis of
one sample of triplicates is shown. C. PC-3 cells (2610
5/well) were
infected in triplicate with YY1siRNA or scrambled control, and evaluated
72 hr later. PSCA message was determined by quantitative real-time PCR
analysis. One independent repeat of the experiment was conducted with
similar results. *=p,0.03. D. Endogenous YY1 protein in YY1siRNA- or
scramble control-infected cells was determined by Western blot.
Representative analysis of one sample of triplicates is shown.
doi:10.1371/journal.pone.0035570.g006
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